Medpace Holdings, Inc. is a contract research organization (CRO) providing comprehensive clinical development services, from early-stage trials to post-market support. They assist pharmaceutical, biotechnology, and medical device clients, primarily smaller companies, across North America, Europe, and Asia. While metabolic work previously drove growth, oncology now represents over half of new bookings and awards. Their top 10 customers account for approximately 39% of revenue.
Key Inputs And Sourcing
1. Labor (Salaries, Wages, Benefits)
Not in registry
labor · Global · unknown
Source Medpace expanded its global workforce to approximately 6,500 employees across 46 countries as of June 30, 2026. The earnings transcript discusses headcount growth and pressures on salaries, wages, and benefits.
Confidence: high
2. Reimbursable Costs / Pass-Through Expenses
Not in registry
other · Global · 40-42% of revenue
Source These are direct costs passed to the sponsor at actual cost, including site and PI grant fees, external vendor costs, travel, and insurance. Kevin Brady stated the reimbursable component of direct costs is expected to be 41-42% of revenue for Q3 and Q4 2026.
Confidence: high
3. Clinical Site & Investigator Fees (Grants)
Not in registry
other · Global · unknown
Source These are a significant part of pass-through costs, paid to principal investigators and sites for patient recruitment and trial execution.
Confidence: high
4. Subcontracted Services / External Vendors
Not in registry
other · Global · unknown
Source Includes costs for central labs, independent data monitoring committees (IDMC), ePRO (electronic patient-reported outcomes) providers, and other specialized services. These are part of pass-through costs.
Confidence: medium
5. Data Management & Technology (Software/Licenses)
Not in registry
component · Global · unknown
Source Costs for electronic data capture (EDC) system licenses, data cleaning, statistical programming, and investments in AI platforms are significant.
Confidence: medium
6. Facilities / Real Estate
Not in registry
other · North America (primarily US) · unknown
Source Medpace is undertaking a significant expansion in Cincinnati, adding approximately $20 million in operating costs in 2027.
Confidence: medium
7. Travel & Logistics
Not in registry
logistics · Global · unknown
Source Costs associated with clinical monitors traveling to sites and other logistical expenses are often billed as pass-throughs.
Confidence: medium
8. Regulatory Fees & Insurance
Not in registry
other · Global · unknown
Source Fees for regulatory submissions (e.g., IND, IDE), safety reporting, audits, and patient insurance are critical costs.
Confidence: medium
Industry Publications
- FierceBiotech (fiercebiotech.com) — Provides daily news on biotechnology innovation, funding, drug approvals, and emerging technologies, including AI-driven drug discovery, which directly impacts Medpace's client base and service offerings. Also covers CRO industry trends and challenges. [cite: 1, 2, 17, 28, Theme_Overview]
- Endpoints News (endpts.com) — Offers in-depth reporting and analysis on the biotechnology and pharmaceutical industries, with strong coverage of financing, deals, and strategic shifts, including those impacting CROs and AI in biopharma. [cite: 14, 15, 20, 25, Theme_Overview]
- Clinical Leader (clinicalleader.com) — Highly relevant for monitoring Medpace's core business, as it focuses on clinical research, trial execution, oversight, and operational challenges within the CRO industry.
- Scrip (pharmaintelligence.informa.com/products/scrip) — Provides global pharmaceutical and biotech news, analysis, and data, including regulatory developments and market trends relevant to CROs. It has also recognized top CROs with awards.
- Life Sciences Review (lifesciencesreview.com) — Features listings of 'Top Contract Research Organizations (CROs)' and covers topics like clinical trials, drug discovery, and biotech, offering insights into Medpace's competitive landscape and industry standing.
Economic Data Watch
1. Federal Reserve Board — H.15 Selected Interest Rates
Not in registry
Metric/field Federal Funds Effective Rate (DFF)
Cadence monthly
Why it matters Influences the cost of capital for growth-oriented biotechnology companies and impacts investor risk appetite for early-stage assets.
Signal to watch Decreasing rate is bullish, increasing rate is bearish.
Confidence: high
2. BEA — National Income and Product Accounts
Not in registryaccess=api
Metric/field Real Gross Domestic Product (A191RL1Q225SBEA)
Cadence quarterly
Why it matters Overall economic growth impacts corporate profitability and R&D budgets across the pharmaceutical and biotech industries.
Signal to watch Increasing growth is bullish, decreasing growth is bearish.
Confidence: high
3. Federal Reserve Board — Industrial Production and Capacity Utilization
Not in registry
Metric/field Industrial Production: Pharmaceuticals and Medicines (NAICS 3254) (IPG3254N)
Cadence monthly
Why it matters Directly reflects production activity in the pharmaceutical sector, indicating demand and investment in drug manufacturing, which can correlate with clinical trial activity.
Signal to watch Increasing production is bullish, decreasing production is bearish.
Confidence: high
4. BLS — Consumer Price Index
Not in registryaccess=api
Metric/field Consumer Price Index for All Urban Consumers: All Items in U.S. City Average (CPIAUCSL)
Cadence monthly
Why it matters High inflation can increase operating costs for CROs and impact overall economic stability, potentially affecting R&D budgets.
Signal to watch Stable or decreasing inflation is bullish, increasing inflation is bearish.
Confidence: high
5. Trading Economics — China Industrial Production
Not in registryaccess=scrape
Metric/field China Industrial Production
Cadence monthly
Why it matters China is a significant market for pharmaceutical R&D and manufacturing. Its industrial health can indicate broader economic trends affecting global biotech investment and activity.
Signal to watch Increasing production is bullish, decreasing production is bearish.
Confidence: high
Free Alt Data Watch
1. ClinicalTrials.gov — Study Records
Not in registry
Metric/field Number of new studies registered with 'Biotechnology' or 'Pharmaceutical' as lead sponsor
Cadence daily
Why it matters Directly indicates the pipeline of new clinical trials, which is the core business for CROs like Medpace.
Signal to watch Increasing new registrations is bullish, decreasing is bearish.
Confidence: high
2. SEC EDGAR — 8-K Filings
Not in registry
Metric/field Number of 8-K filings by biotech/pharma companies related to funding, M&A, or clinical trial results
Cadence daily
Why it matters Provides real-time insights into significant events affecting Medpace's client base, such as funding rounds or M&A, which can impact project continuity or new business.
Signal to watch Increased positive funding/trial news is bullish, increased negative news or M&A (for Medpace's clients) is bearish.
Confidence: medium
3. Google Trends — Search Interest Data
Not in registry
Metric/field Search interest for 'AI drug discovery' (worldwide)
Cadence weekly
Why it matters Indicates public and industry interest in the core technology driving the theme, signaling broader awareness and potential adoption.
Signal to watch Increasing search interest is bullish, decreasing is bearish.
Confidence: high
4. Medpace Holdings, Inc. Investor Relations — Press Releases
Not in registry
Metric/field Number and content of press releases related to new business awards, partnerships, or operational updates
Cadence irregular
Why it matters Direct announcements from the company provide immediate insight into business momentum, new client wins, and strategic developments.
Signal to watch Positive announcements (new awards, strong partnerships) are bullish, lack of updates or negative news is bearish.
Confidence: high
5. USPTO PatentsView — Patent Grants
Not in registry
Metric/field Number of patent grants in biotechnology and pharmaceutical fields by assignee (small/mid-cap companies)
Cadence monthly
Why it matters Indicates innovation and R&D output within the biotech and pharmaceutical industries, which drives future clinical trial demand.
Signal to watch Increasing patent activity from Medpace's target client base is bullish, decreasing activity is bearish.
Confidence: medium
Paid Alt Data Watch
1. Revelio Labs — Jobs / Workforce Data
Not in registryaccess=file
Metric/field Total job postings for 'Clinical Research Associate' OR 'Clinical Project Manager' within CRO industry
Cadence monthly
Why it matters Hiring trends for key roles in CROs indicate industry capacity expansion and demand for clinical trial services.
Signal to watch Increasing job postings are bullish, decreasing are bearish.
Confidence: high
2. Norstella / GlobalData Healthcare / Clarivate Life Sciences & Healthcare — Healthcare Claims / Rx Data
Matchednorstella_clinical_trials_catalysts · access=file · map_only
Metric/field Number of active clinical trials by therapeutic area (Oncology, Metabolic) and phase
Cadence monthly
Why it matters Provides granular insight into the therapeutic mix and phase distribution of ongoing clinical trials, directly impacting Medpace's project pipeline and specialization.
Signal to watch Increasing trials in Medpace's focus areas (e.g., Oncology) is bullish, decreasing is bearish.
Confidence: high
3. PitchBook / Crunchbase / CB Insights — Venture Capital Funding Data
Not in registry
Metric/field Total venture capital funding rounds and dollar value for small/mid-cap biotechnology companies
Cadence quarterly
Why it matters Directly tracks the funding environment for Medpace's primary client base, indicating their capacity to initiate and fund new clinical trials.
Signal to watch Increasing funding is bullish, decreasing is bearish.
Confidence: high
4. Similarweb / Datos — Web Traffic Data
Matchedsimilarweb_website_traffic_engagement · access=file · map_only
Metric/field Website traffic to Medpace's corporate and investor relations pages
Cadence monthly
Why it matters Indicates investor and industry interest in Medpace, potentially correlating with business development activity or market sentiment.
Signal to watch Increasing traffic (especially to IR pages) is bullish, decreasing is bearish.
Confidence: medium
5. IQVIA — R&D Spend Forecasts
Not in registry
Metric/field Global Biopharmaceutical R&D spending forecasts and actuals
Cadence quarterly
Why it matters Provides a macro view of the overall R&D investment by the biopharmaceutical industry, which drives demand for CRO services.
Signal to watch Increasing R&D spend is bullish, decreasing is bearish.
Confidence: high
Search Keywords Brand Product
- contract research organization
- CRO services
- clinical development
- clinical trials
- drug discovery
- biotechnology research
- pharmaceutical research
- medical device trials
- oncology trials
- metabolic disease research
- Phase I-IV clinical trials
- bioanalytical laboratory services
- ECG core laboratory
- imaging services
Search Keywords Event Phrases
- Medpace earnings
- Medpace Q3 2026 results
- AI drug discovery summit
- biotech AI partnerships
Search Keywords Policy Regulatory
- FDA AI drug development guidance
- EMA AI in pharma regulation
- AI clinical trial guidelines
- What They Do (Plain English & Analogies)
- Medpace acts like a specialized, outsourced research and development department for companies that are creating new medicines, medical devices, or other health treatments. Instead of these pharmaceutical, biotechnology, and medical device companies doing all the complex and time-consuming testing themselves, they hire Medpace. Medpace handles the entire process of clinical trials, from the very first tests in humans (Phase I) all the way through to post-market support (Phase IV). This includes designing the studies, managing patient data, ensuring everything follows strict government rules, running the trials, analyzing the results, and providing specialized lab testing like bio-analytical, ECG, and imaging services. Essentially, they help bring new treatments to market faster and more efficiently by providing a comprehensive, integrated platform for clinical research. Think of them as a highly specialized general contractor for drug and device development, managing all the intricate steps from blueprint to final approval.
- Very Brief History
- Medpace Holdings, Inc. was founded in Cincinnati, Ohio, in 1992 as Medical Research Services. Over the years, it has evolved into a global contract research organization (CRO) providing a comprehensive suite of clinical development and research services across various therapeutic areas. The company started trading stock as a public firm in 2016.
- "Street Stereotype"
- The 'Street stereotype' for Medpace often involves scrutiny over its valuation, with investors perceiving it as having a premium multiple. This perception is amplified by recent concerns about slowing sequential growth and a declining backlog coverage beyond the next 12 months. The market is particularly focused on whether Medpace's growth trajectory can justify its valuation, especially given the recent negative reaction to booking trends and future growth prospects.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Medpace's customers are primarily in the pharmaceutical, biotechnology, and medical device industries. They specifically focus on serving virtual and smaller companies, rather than large pharmaceutical firms. While specific client names are not disclosed due to confidentiality, their customer base consists of numerous small to mid-sized biotech and pharma firms developing new therapies and devices.
- New Customers / Segments They'Re Targeting
- Medpace is not explicitly targeting entirely new customer types or segments beyond its existing focus on pharmaceutical, biotechnology, and medical device clients. Instead, the company is focused on improving its win rate within its existing client base and adapting to shifts in therapeutic demand, such as the current pivot back towards oncology from metabolic work.
- Sales Geographies And Expansion Plans
- Medpace currently sells its services geographically across North America, Europe, and Asia. The company also has a presence in Latin America and South Africa. Management has not indicated specific plans to expand sales into new geographies, but rather focuses on expanding its pipeline and improving its win rate within its existing global footprint. Operationally, Medpace is bringing a significant expansion online in Cincinnati, which will add about $20 million in operating costs in 2027.
- How Key Themes May Help/Hurt
- The 'Biotech '26: AI Driven Drug Discovery' theme presents both opportunities and challenges for Medpace. The company expects to invest significantly in AI over the next two years, anticipating net benefits in efficiency only a few years down the line. This substantial upfront capital investment could create a drag on near-term profitability and operational efficiency before long-term gains are realized. However, the widespread integration of AI tools across the biotech value chain, from target identification to clinical trial optimization, could ultimately enhance Medpace's service offerings, streamline its operations, and improve data quality and trial efficiency, aligning with the broader industry trend of accelerating drug development timelines and costs.
3 Main Long-Term Bull Details
- Specialized Full-Service Model: Medpace's comprehensive, internally-driven, full-service model for clinical development is highly valued by smaller and virtual biotech companies, allowing them to outsource complex R&D efficiently and providing a single, accountable partner for clinical research, data, labs, and regulatory support.
- Strong Financial Performance & Cash Generation: The company has demonstrated robust financial performance, with significant revenue and EBITDA growth, strong cash flow from operating activities, and a healthy cash balance, indicating operational efficiency and financial stability.
- High-Quality Opportunity Flow & Improving Business Environment: Medpace is experiencing a strong business environment with record net bookings, reduced cancellations, and increasing RFPs of good quality, suggesting sustained demand for its specialized services and a healthy pipeline for future growth.
3 Main Long-Term Bear Details
- Backlog Volatility and Conversion Rate: While the third quarter of 2026 saw strong net new business awards, concerns about the long-term backlog coverage persist. The backlog conversion rate, while currently at 23.8%, is influenced by policy implementations regarding decision points in trials, and its future trajectory is uncertain, potentially impacting future revenue visibility.
- Exposure to Biotech Funding Volatility and M&A Impact: Medpace's client base, primarily smaller and virtual biotechs, is inherently sensitive to fluctuations in capital markets and biotech funding. Additionally, client acquisitions by larger pharmaceutical companies can be detrimental, as acquired clients may cut Medpace out of future work, creating ongoing competitive pressure.
- Initial AI Investment Outweighs Near-Term Benefits: Management expects to invest significantly in AI over the next two years, with the anticipation of net benefits in efficiency only a few years down the line. This substantial upfront capital investment could create a drag on near-term profitability and operational efficiency before long-term gains are realized.
- Competitors And Differentiation
- Medpace's competitors include large, full-service CROs such as IQVIA, ICON plc, Labcorp (Drug Development/Fortrea), Charles River Laboratories, Parexel, PPD (part of Thermo Fisher Scientific), and Syneos Health. Medpace differentiates itself through its scientifically-driven, global, full-service CRO model, particularly serving smaller to mid-sized biotech companies. They emphasize their integrated services, medical and regulatory expertise, and a collaborative model. The company also highlights its organic growth model and aims for close, individual relationships with its partners, focusing on the quality of its deliverables rather than aggressive pricing.
- Recent Performance & What The Market'S Focused On
- Medpace reported a strong third quarter of 2026, with revenue of $716 million, an 8.5% year-over-year increase. Net income increased 23.7% to $137.5 million, or $4.84 per diluted share. EBITDA grew 16% to $172.1 million, with an EBITDA margin of 24%. Net new business awards reached an all-time high of $873 million, a 10.6% increase year-over-year, and the last 12-month closing awards increased 23.9%. Ending backlog as of September 30, 2026, was approximately $3.2 billion, up 5.6% from the prior year. The company updated its full-year 2026 guidance, expecting total revenue in the range of $2.835 billion to $2.855 billion, and diluted EPS in the range of $17.97 to $18.32. For 2027, management indicated that current analyst consensus estimates appear reasonable. The market is focused on the strong bookings performance, the sustainability of the improved win rate, the impact of cancellations (which were higher than desired in Q3 but manageable), and the evolving therapeutic mix with a return to oncology.
- Revenue Segments And Estimated Mix
- Oncology — Mix: Large area, increasing in new awards and opportunities; Source: Q3 2026 earnings transcript; Trend: Pivoting back towards traditional oncology, with strong pending opportunities.
- Cardiometabolic (including GLP-1 related work) — Mix: Significant segment, but less demand at current time point for new awards, though pending opportunities are strong; Source: Q3 2026 earnings transcript; Trend: Less metabolic demand at current time point in terms of awards, but a lot of pending opportunities for metabolic work.
- Other Therapeutic Areas — Mix: n/m; Source: Q3 2026 earnings transcript; Trend: Cancellations in Q1 2026 were noted in oncology and cardiovascular, considered usual.
- Product Brands
- {"brands":[]}